Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Gene Therapy in Treating Patients With Recurrent Malignant Gliomas
Phase I Trial of Adenovirus-Mediated Wild-Type P53 Gene Therapy for Malignant Gliomas
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Gene Therapy in Treating Patients With Recurrent Malignant Gliomas
Phase I Trial of Adenovirus-Mediated Wild-Type P53 Gene Therapy for Malignant Gliomas
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Gene Therapy in Treating Patients With Recurrent Malignant Gliomas
Phase I Trial of Adenovirus-Mediated Wild-Type P53 Gene Therapy for Malignant Gliomas
Status: Enrolling
Updated:  12/31/1969
Simmons Cancer Center - Dallas
mi
from
Dallas, TX
Gene Therapy in Treating Patients With Recurrent Malignant Gliomas
Phase I Trial of Adenovirus-Mediated Wild-Type P53 Gene Therapy for Malignant Gliomas
Status: Enrolling
Updated: 12/31/1969
Simmons Cancer Center - Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Gene Therapy in Treating Patients With Recurrent Malignant Gliomas
Phase I Trial of Adenovirus-Mediated Wild-Type P53 Gene Therapy for Malignant Gliomas
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Gene Therapy in Treating Patients With Recurrent Malignant Gliomas
Phase I Trial of Adenovirus-Mediated Wild-Type P53 Gene Therapy for Malignant Gliomas
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Gene Therapy in Treating Patients With Recurrent Malignant Gliomas
Phase I Trial of Adenovirus-Mediated Wild-Type P53 Gene Therapy for Malignant Gliomas
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Gene Therapy in Treating Patients With Recurrent Malignant Gliomas
Phase I Trial of Adenovirus-Mediated Wild-Type P53 Gene Therapy for Malignant Gliomas
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Gene Therapy in Treating Patients With Recurrent Malignant Gliomas
Phase I Trial of Adenovirus-Mediated Wild-Type P53 Gene Therapy for Malignant Gliomas
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Gene Therapy in Treating Patients With Recurrent Malignant Gliomas
Phase I Trial of Adenovirus-Mediated Wild-Type P53 Gene Therapy for Malignant Gliomas
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy
A Phase I/II Trial of SU5416 in Patients With Recurrent High Grade Astrocytomas or Mixed Gliomas
Status: Enrolling
Updated:  12/31/1969
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy
A Phase I/II Trial of SU5416 in Patients With Recurrent High Grade Astrocytomas or Mixed Gliomas
Status: Enrolling
Updated: 12/31/1969
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy
A Phase I/II Trial of SU5416 in Patients With Recurrent High Grade Astrocytomas or Mixed Gliomas
Status: Enrolling
Updated:  12/31/1969
UCSF Cancer Center and Cancer Research Institute
mi
from
San Francisco, CA
SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy
A Phase I/II Trial of SU5416 in Patients With Recurrent High Grade Astrocytomas or Mixed Gliomas
Status: Enrolling
Updated: 12/31/1969
UCSF Cancer Center and Cancer Research Institute
mi
from
San Francisco, CA
Click here to add this to my saved trials
SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy
A Phase I/II Trial of SU5416 in Patients With Recurrent High Grade Astrocytomas or Mixed Gliomas
Status: Enrolling
Updated:  12/31/1969
Neuro-Oncology Branch
mi
from
Bethesda, MD
SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy
A Phase I/II Trial of SU5416 in Patients With Recurrent High Grade Astrocytomas or Mixed Gliomas
Status: Enrolling
Updated: 12/31/1969
Neuro-Oncology Branch
mi
from
Bethesda, MD
Click here to add this to my saved trials
SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy
A Phase I/II Trial of SU5416 in Patients With Recurrent High Grade Astrocytomas or Mixed Gliomas
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy
A Phase I/II Trial of SU5416 in Patients With Recurrent High Grade Astrocytomas or Mixed Gliomas
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy
A Phase I/II Trial of SU5416 in Patients With Recurrent High Grade Astrocytomas or Mixed Gliomas
Status: Enrolling
Updated:  12/31/1969
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy
A Phase I/II Trial of SU5416 in Patients With Recurrent High Grade Astrocytomas or Mixed Gliomas
Status: Enrolling
Updated: 12/31/1969
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy
A Phase I/II Trial of SU5416 in Patients With Recurrent High Grade Astrocytomas or Mixed Gliomas
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy
A Phase I/II Trial of SU5416 in Patients With Recurrent High Grade Astrocytomas or Mixed Gliomas
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy
A Phase I/II Trial of SU5416 in Patients With Recurrent High Grade Astrocytomas or Mixed Gliomas
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy
A Phase I/II Trial of SU5416 in Patients With Recurrent High Grade Astrocytomas or Mixed Gliomas
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy
A Phase I/II Trial of SU5416 in Patients With Recurrent High Grade Astrocytomas or Mixed Gliomas
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy
A Phase I/II Trial of SU5416 in Patients With Recurrent High Grade Astrocytomas or Mixed Gliomas
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy
A Phase I/II Trial of SU5416 in Patients With Recurrent High Grade Astrocytomas or Mixed Gliomas
Status: Enrolling
Updated:  12/31/1969
Simmons Cancer Center - Dallas
mi
from
Dallas, TX
SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy
A Phase I/II Trial of SU5416 in Patients With Recurrent High Grade Astrocytomas or Mixed Gliomas
Status: Enrolling
Updated: 12/31/1969
Simmons Cancer Center - Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy
A Phase I/II Trial of SU5416 in Patients With Recurrent High Grade Astrocytomas or Mixed Gliomas
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy
A Phase I/II Trial of SU5416 in Patients With Recurrent High Grade Astrocytomas or Mixed Gliomas
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy
A Phase I/II Trial of SU5416 in Patients With Recurrent High Grade Astrocytomas or Mixed Gliomas
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy
A Phase I/II Trial of SU5416 in Patients With Recurrent High Grade Astrocytomas or Mixed Gliomas
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy
A Phase I/II Trial of SU5416 in Patients With Recurrent High Grade Astrocytomas or Mixed Gliomas
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy
A Phase I/II Trial of SU5416 in Patients With Recurrent High Grade Astrocytomas or Mixed Gliomas
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
Phase I-II Trial of CPT-11 and Temozolomide (Temodar) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
Phase I-II Trial of CPT-11 and Temozolomide (Temodar) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
Phase I-II Trial of CPT-11 and Temozolomide (Temodar) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
UCSF Comprehensive Cancer Center
mi
from
San Francisco, CA
Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
Phase I-II Trial of CPT-11 and Temozolomide (Temodar) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
UCSF Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
Phase I-II Trial of CPT-11 and Temozolomide (Temodar) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
mi
from
Bethesda, MD
Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
Phase I-II Trial of CPT-11 and Temozolomide (Temodar) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
mi
from
Bethesda, MD
Click here to add this to my saved trials
Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
Phase I-II Trial of CPT-11 and Temozolomide (Temodar) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
Phase I-II Trial of CPT-11 and Temozolomide (Temodar) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
Phase I-II Trial of CPT-11 and Temozolomide (Temodar) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
Phase I-II Trial of CPT-11 and Temozolomide (Temodar) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
Phase I-II Trial of CPT-11 and Temozolomide (Temodar) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
Hillman Cancer Center at University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
Phase I-II Trial of CPT-11 and Temozolomide (Temodar) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
Hillman Cancer Center at University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
Phase I-II Trial of CPT-11 and Temozolomide (Temodar) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
Phase I-II Trial of CPT-11 and Temozolomide (Temodar) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
Phase I-II Trial of CPT-11 and Temozolomide (Temodar) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
Phase I-II Trial of CPT-11 and Temozolomide (Temodar) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
Phase I-II Trial of CPT-11 and Temozolomide (Temodar) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
Phase I-II Trial of CPT-11 and Temozolomide (Temodar) in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Fenretinide in Treating Patients With Recurrent Malignant Glioma
Phase II Evaluation of Fenretinide NSC (374551) as a Single Agent in the Treatment of Adult Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Fenretinide in Treating Patients With Recurrent Malignant Glioma
Phase II Evaluation of Fenretinide NSC (374551) as a Single Agent in the Treatment of Adult Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Fenretinide in Treating Patients With Recurrent Malignant Glioma
Phase II Evaluation of Fenretinide NSC (374551) as a Single Agent in the Treatment of Adult Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
UCSF Cancer Center and Cancer Research Institute
mi
from
San Francisco, CA
Fenretinide in Treating Patients With Recurrent Malignant Glioma
Phase II Evaluation of Fenretinide NSC (374551) as a Single Agent in the Treatment of Adult Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
UCSF Cancer Center and Cancer Research Institute
mi
from
San Francisco, CA
Click here to add this to my saved trials
Fenretinide in Treating Patients With Recurrent Malignant Glioma
Phase II Evaluation of Fenretinide NSC (374551) as a Single Agent in the Treatment of Adult Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
mi
from
Bethesda, MD
Fenretinide in Treating Patients With Recurrent Malignant Glioma
Phase II Evaluation of Fenretinide NSC (374551) as a Single Agent in the Treatment of Adult Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
mi
from
Bethesda, MD
Click here to add this to my saved trials
Fenretinide in Treating Patients With Recurrent Malignant Glioma
Phase II Evaluation of Fenretinide NSC (374551) as a Single Agent in the Treatment of Adult Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Fenretinide in Treating Patients With Recurrent Malignant Glioma
Phase II Evaluation of Fenretinide NSC (374551) as a Single Agent in the Treatment of Adult Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Fenretinide in Treating Patients With Recurrent Malignant Glioma
Phase II Evaluation of Fenretinide NSC (374551) as a Single Agent in the Treatment of Adult Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Fenretinide in Treating Patients With Recurrent Malignant Glioma
Phase II Evaluation of Fenretinide NSC (374551) as a Single Agent in the Treatment of Adult Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Fenretinide in Treating Patients With Recurrent Malignant Glioma
Phase II Evaluation of Fenretinide NSC (374551) as a Single Agent in the Treatment of Adult Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Fenretinide in Treating Patients With Recurrent Malignant Glioma
Phase II Evaluation of Fenretinide NSC (374551) as a Single Agent in the Treatment of Adult Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Fenretinide in Treating Patients With Recurrent Malignant Glioma
Phase II Evaluation of Fenretinide NSC (374551) as a Single Agent in the Treatment of Adult Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Fenretinide in Treating Patients With Recurrent Malignant Glioma
Phase II Evaluation of Fenretinide NSC (374551) as a Single Agent in the Treatment of Adult Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Fenretinide in Treating Patients With Recurrent Malignant Glioma
Phase II Evaluation of Fenretinide NSC (374551) as a Single Agent in the Treatment of Adult Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
Simmons Cancer Center - Dallas
mi
from
Dallas, TX
Fenretinide in Treating Patients With Recurrent Malignant Glioma
Phase II Evaluation of Fenretinide NSC (374551) as a Single Agent in the Treatment of Adult Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
Simmons Cancer Center - Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Fenretinide in Treating Patients With Recurrent Malignant Glioma
Phase II Evaluation of Fenretinide NSC (374551) as a Single Agent in the Treatment of Adult Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Fenretinide in Treating Patients With Recurrent Malignant Glioma
Phase II Evaluation of Fenretinide NSC (374551) as a Single Agent in the Treatment of Adult Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Fenretinide in Treating Patients With Recurrent Malignant Glioma
Phase II Evaluation of Fenretinide NSC (374551) as a Single Agent in the Treatment of Adult Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Fenretinide in Treating Patients With Recurrent Malignant Glioma
Phase II Evaluation of Fenretinide NSC (374551) as a Single Agent in the Treatment of Adult Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Fenretinide in Treating Patients With Recurrent Malignant Glioma
Phase II Evaluation of Fenretinide NSC (374551) as a Single Agent in the Treatment of Adult Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Fenretinide in Treating Patients With Recurrent Malignant Glioma
Phase II Evaluation of Fenretinide NSC (374551) as a Single Agent in the Treatment of Adult Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma
Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas
Status: Enrolling
Updated:  12/31/1969
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma
Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas
Status: Enrolling
Updated: 12/31/1969
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma
Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas
Status: Enrolling
Updated:  12/31/1969
UCSF Comprehensive Cancer Center
mi
from
San Francisco, CA
Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma
Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas
Status: Enrolling
Updated: 12/31/1969
UCSF Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma
Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas
Status: Enrolling
Updated:  12/31/1969
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
mi
from
Bethesda, MD
Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma
Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas
Status: Enrolling
Updated: 12/31/1969
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
mi
from
Bethesda, MD
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma
Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas
Status: Enrolling
Updated:  12/31/1969
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma
Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas
Status: Enrolling
Updated: 12/31/1969
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma
Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas
Status: Enrolling
Updated:  12/31/1969
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma
Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas
Status: Enrolling
Updated: 12/31/1969
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma
Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma
Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma
Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas
Status: Enrolling
Updated:  12/31/1969
Hillman Cancer Center at University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma
Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas
Status: Enrolling
Updated: 12/31/1969
Hillman Cancer Center at University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma
Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas
Status: Enrolling
Updated:  12/31/1969
Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas
mi
from
Dallas, TX
Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma
Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas
Status: Enrolling
Updated: 12/31/1969
Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma
Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma
Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma
Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma
Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma
Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma
Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma
A Phase I Study Of ZD 1839 And Temozolomide For The Treatment Of Gliomas
Status: Enrolling
Updated:  12/31/1969
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma
A Phase I Study Of ZD 1839 And Temozolomide For The Treatment Of Gliomas
Status: Enrolling
Updated: 12/31/1969
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma
A Phase I Study Of ZD 1839 And Temozolomide For The Treatment Of Gliomas
Status: Enrolling
Updated:  12/31/1969
UCSF Comprehensive Cancer Center
mi
from
San Francisco, CA
Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma
A Phase I Study Of ZD 1839 And Temozolomide For The Treatment Of Gliomas
Status: Enrolling
Updated: 12/31/1969
UCSF Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials